The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial

Autor: V. C. Rutten, Y. Salhi, G. J. Robbrecht, R. de Wit, G. J.L.H. van Leenders, T. C.M. Zuiverloon, J. L. Boormans

Publikováno v: BMC Cancer, Vol 23, Iss 1, Pp 1-6 (2023)

Abstract Background Patients with locally advanced irresectable or clinically node positive urothelial cancer (UC) have a poor outcome. Currently, these patients can only be cured by receiving induction chemotherapy and, if an adequate radiological r

Externí odkaz: https://doaj.org/article/8578b599277441c687e88d3879ec2860

Incidence of metachronous contralateral testicular germ cell tumour and association with chemotherapy

Autor: J.M. Blok, H.J. Groot, E.H. Huele, R. De Wit, J.A. Gietema, G. Groenewegen, J.A. Witjes, H.A. Van Den Berg, J. Nuver, J.M. Tromp, P.J.M. De Brouwer, T.J. Smilde, M.J.B. Aarts, B.G.L. Vanneste, J.L.H.R. Bosch, S. Horenblas, M. Schaapveld, R.P. Meijer

Publikováno v: European Urology Open Science, Vol 19, Iss , Pp e405-e406 (2020)

Externí odkaz: https://doaj.org/article/9e0091c7484a4617b7a368a8b7769e81

Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

Autor: J.L. Boormans, R. De Wit, G.S. Kulkarni, E.M. Uchio, M. Roumiguié, L.E.M. Krieger, E.A. Singer, D.F. Bajorin, A.M. Kamat, P. Grivas, H.K. Seo, H. Nishiyama, B.R. Konethy, T. Saretsky, H. Li, K. Nam, E. Kapadia, A.V. Balar

Publikováno v: European Urology Open Science, Vol 19, Iss , Pp e1173-e1174 (2020)

Externí odkaz: https://doaj.org/article/8962551a8bdb44f585ab6b994e58bb8b

Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset

Autor: Amy Matser, Godelieve J. de Bree, Neeltje A. Kootstra, Anders Boyd, Marije R. de Wit, Menno D. de Jong, Joost G. van den Aardweg, Hugo D.G. van Willigen, Tjalling Leenstra, Marit J. van Gils, Maria Prins, Maartje Dijkstra, Elke Wynberg

Publikováno v: Clinical infectious diseases, 75(1), e482-e490. Oxford University Press
Clinical Infectious Diseases, 75(1), e482-e490. Oxford University Press
RECoVERED Study Group 2022, ' Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset ', Clinical Infectious Diseases, vol. 75, no. 1, pp. e482-e490 . https://doi.org/10.1093/cid/ciab759

Background Few robust longitudinal data on long-term coronavirus disease 2019 (COVID-19) symptoms are available. We evaluated symptom onset, severity and recovery across the full spectrum of disease severity, up to one year after illness onset. Metho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe9a59ec366a848b3237bef834cffd97
https://doi.org/10.1093/cid/ciab759

Novel treatment options in the management of metastatic castration-naïve prostate cancer; Which treatment modality to choose?

Autor: Martijn P. Lolkema, R.J. van Soest, Ron H.J. Mathijssen, Bodine P.S. Belderbos, R. de Wit

Publikováno v: Annals of Oncology, 30(10), 1591-1600. Elsevier Ltd.

Androgen-deprivation therapy (ADT) has been the mainstay of treatment of metastatic prostate cancer since the first report of its hormonal dependence in the 1940s. Since 2015, the addition of docetaxel and the addition of abiraterone to ADT have conf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e5c151399bbaa966539bc4ab9563ece
http://www.scopus.com/inward/record.url?scp=85071727312&partnerID=8YFLogxK